Amgen Inc (AMGN)vsBP PLC ADR (BP)
AMGN
Amgen Inc
$353.93
+1.58%
HEALTHCARE · Cap: $187.83B
BP
BP PLC ADR
$44.79
+2.80%
ENERGY · Cap: $114.71B
Smart Verdict
WallStSmart Research — data-driven comparison
BP PLC ADR generates 411% more annual revenue ($187.64B vs $36.75B). AMGN leads profitability with a 21.0% profit margin vs 0.0%. BP appears more attractively valued with a PEG of 0.18. AMGN earns a higher WallStSmart Score of 70/100 (B-).
AMGN
Strong Buy70
out of 100
Grade: B-
BP
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.8%
Fair Value
$665.50
Current Price
$353.93
$311.57 discount
Margin of Safety
-4001.1%
Fair Value
$0.94
Current Price
$44.79
$43.85 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Growing faster than its price suggests
Large-cap with strong market position
Generating 4.1B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 22.0x book value
Trading at 13.0x book value
3.6% revenue growth
ROE of 1.7% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : BP
The strongest argument for BP centers on PEG Ratio, Market Cap, Free Cash Flow. PEG of 0.18 suggests the stock is reasonably priced for its growth.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book.
Bear Case : BP
The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2239.0x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
AMGN profiles as a mature stock while BP is a value play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.42 — expect wider price swings.
AMGN is growing revenue faster at 8.6% — sustainability is the question.
BP generates stronger free cash flow (4.1B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (70/100 vs 54/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →BP PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?